I

n another setback to Sanofi (SNY), the Philippine government has suspended clearance for is dengue vaccine and fined the company a symbolic $2,000 for allegedly failing to comply with product-registration terms.

The move comes less than two months after the drug maker caused a public health uproar by reporting that Dengvaxia could worsen — rather than prevent — future cases of the mosquito-borne virus in people who had not previously been infected. Approximately 800,000 children in the Philippines were vaccinated as part of a government-sponsored program.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy